Japan· JP-4291430A1026
イピリムマブ（遺伝子組換え）
A ipilimumab product containing イピリムマブ（遺伝子組換え）, registered in Japan by ブリストル・マイヤーズ スクイブ, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Ipilimumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX04 (ipilimumab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Ipilimumab · ATC L01FX04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ipilimumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ipilimumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$884.82
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- イピリムマブ（遺伝子組換え）
- Manufacturer
- ブリストル・マイヤーズ スクイブ
- Country
- Japan (JP)
- ATC code
- L01FX04
- ATC class
- Ipilimumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
157 interactions on record for ipilimumab.
Graded by severity as the source publishes them — 25 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ipilimumab · interactions on record
157 records
- 25 severe
- 132 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ipilimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesYERVOYE.R. Squibb & Sons, L.L.C.
- United KingdomYervoy 200mg/40ml concentrate for solution for infusion vialsOriginalis B.V.
- SpainYERVOY 5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandYERVOYOrifarm Oy
- BelgiumYervoy 5 mg/mlBristol-Myers Squibb Pharma
- SwitzerlandYERVOY 200 mg/40 ml, Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- CzechiaYERVOYBristol-Myers Squibb Pharma EEIG, Dublin
- NorwayYervoyBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yervoy
- Liechtenstein · Yervoy
- Norway · Yervoy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8599d6d2-e9ad-477f-8e46-8f1112e4d760 GET /v1/drugs/8599d6d2-e9ad-477f-8e46-8f1112e4d760?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ１０ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291430A1026",
"category": "注射薬",
"price_yen": 419578,
"generic_name": "イピリムマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about ipilimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.